| Literature DB >> 18155811 |
E F Carniel1, A M Morcillo, M H Blotta, M T N Da Silva, T N Mazzola, M A R G M Antonio, M L Zanolli, A Aranha Netto, H G Higashi, I Raw, M M S Vilela.
Abstract
This randomized, prospective, non-inferiority study aimed to quantify anti-HBs titers induced by recombinant Hepatitis B vaccine from healthy infants vaccinated with combined Hepatitis B and Bacillus Calmette-Guérin (BCG) vaccines (HbsAg 10 microg plus BCG suspension 0.1mg) and compare them to titers obtained with separated vaccines. Infants were immunized at birth either with combined intradermal (ID) BCG and Hepatitis B or ID BCG alone and intramuscular (IM) Hepatitis B. Both groups received IM Hepatitis B at 1 and 6 months of age. After the third dose anti-HBs titers > or =10 IU/mL were observed in 99% of vaccinees and > or =1000 IU/mL in 71%. There were no adverse events in both groups. Combination of HbsAg with BCG as first dose did not modify the profile of the humoral immune response for Hepatitis B indicating safety and immunogenicity of this vaccine in newborn.Entities:
Mesh：
Substances：
Year: 2007 PMID： 18155811 DOI： 10.1016/j.vaccine.2007.11.048
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641